Department of Propaedeutic and Integrated Clinic, Universidade Federal da Bahia (UFBA), Salvador, Bahia, Brazil.
College of Dentistry, University of Florida, Gainesville, FL, USA.
Oral Surg Oral Med Oral Pathol Oral Radiol. 2023 May;135(5):626-641. doi: 10.1016/j.oooo.2022.12.010. Epub 2022 Dec 28.
Our objective was to review the first 20 years of photobiomodulation (PBM) clinical studies for oral mucositis (OM) mitigation.
A scoping review screened controlled clinical studies. The PBM devices, protocols, and clinical outcomes were analyzed.
Seventy-five studies met the inclusion criteria. The first study dated from 1992, and the term "PBM" was first published in 2017. Public services, placebo-controlled randomized trials, and patients with head and neck chemoradiation were predominant among included studies. Prophylactic red intraoral laser protocols were mostly used. Comparing the outcomes of all protocols was unfeasible due to missing treatment parameters and nonhomogeneous measurements.
The main barrier to optimizing clinical protocols of PBM for OM was the lack of standardization in clinical studies. Although PBM use is now globally present in oncology settings and generally marked by good outcomes reported, additional randomized clinical trials with well-described methods are necessary.
我们旨在回顾光生物调节（PBM）治疗口腔黏膜炎（OM）的前 20 年临床研究。
范围审查筛选了对照临床试验。分析了 PBM 设备、方案和临床结果。
75 项研究符合纳入标准。第一项研究始于 1992 年，“PBM”一词于 2017 年首次发表。纳入的研究主要是公共服务、安慰剂对照随机试验和头颈部放化疗患者。预防性红色口腔内激光方案大多被使用。由于缺少治疗参数和非均质测量，比较所有方案的结果是不可行的。
优化 PBM 治疗 OM 的临床方案的主要障碍是临床研究缺乏标准化。尽管 PBM 的使用现在在肿瘤学领域已经全球化，并且通常报告了良好的结果，但仍需要更多描述性方法的随机临床试验。
